Amylyx Pharmaceuticals, Inc.
AMLX$117.60B
Large CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCAMBRIDGE123 employees
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Apr 1, 2026
4dMarket Overview
Stock performance and key metrics
AMLX News
Catalyst Timeline
1 upcoming, 2 past
Phase 3Next
AMX0035 Phase 3 Results Expected
Apr 1, 2026EstimatedAMX0035110
Primary completion for AMX0035 trial (NCT06122662) in Progressive Supranuclear Palsy
SourceDrug Pipeline
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply